Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of
2 Articles
2 Articles
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual ...
Presentations to cover progress across Eikon’s most advanced clinical-stage programsUpdated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC”), EIK1003, as a monotherapy or in combination in the treatment…
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of
Presentations to cover progress across Eikon's most advanced clinical-stage programs Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ("NSCLC"), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
